Symeres, Ambagon Partner on Novel Cancer Drug Approach
Symeres has entered into a strategic collaboration with Ambagon Therapeutics to explore a promising new class of small molecules known as molecular glues for the treatment of colorectal cancer and other difficult-to-target diseases.
The partnership aims to advance early-stage research into molecular glues, an emerging therapeutic modality that works by enabling or stabilizing interactions between proteins. Unlike traditional drugs that typically inhibit or activate a single protein, molecular glues can bring proteins together, potentially unlocking previously “undruggable” targets within the human proteome. This approach is increasingly seen as a way to expand treatment possibilities while minimizing toxicity associated with conventional therapies.
As part of the collaboration, Symeres will conduct a comprehensive evaluation of Ambagon’s proprietary molecular glue compounds. The research will include a series of in vitro assays and mechanistic studies designed to better understand how these molecules behave and interact at a cellular level. A key component of the work involves analyzing ternary complex kinetics using advanced surface plasmon resonance technology, specifically the ResidenceTimer™ platform.
In addition to kinetic studies, the project will incorporate a range of cellular and molecular biology techniques. Fluorescence microscopy will be used to assess whether the molecular glues can inhibit the nuclear translocation of specific target proteins, a process often implicated in cancer progression. Downstream effects on disease-related pathways will be evaluated through quantitative polymerase chain reaction (qPCR) and Western blot analyses, providing insights into gene and protein expression changes.
The collaboration will also include cancer cell viability assays to determine the therapeutic potential of these compounds across various models. Symeres plans to further support the development process by leveraging its broader capabilities, including compound synthesis, validation, and profiling across a panel of 102 cancer cell lines. This integrated approach is intended to help identify promising candidates earlier and accelerate their progression toward investigational new drug (IND) applications.
Industry experts note that targeting previously inaccessible proteins remains a major challenge in oncology drug discovery. By combining Ambagon’s innovative molecular glue platform with Symeres’ translational research expertise, the collaboration seeks to generate actionable data that could inform future drug development strategies.
The agreement underscores a broader trend in the pharmaceutical industry toward investing in novel therapeutic modalities that can address complex diseases such as colorectal cancer. As research into molecular glues continues to evolve, partnerships like this are expected to play a critical role in translating early scientific discoveries into potential clinical solutions for patients with limited treatment options.